The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 18, 2018

Filed:

Jun. 01, 2015
Applicants:

Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;

Université Paris Descartes, Paris, FR;

Inventor:

Patricia Forgez, Paris, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 16/26 (2006.01); A61K 39/395 (2006.01); A61K 33/24 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07K 16/26 (2013.01); A61K 33/24 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 39/39558 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01);
Abstract

The present invention relates to a neutralizing antibody which is capable of binding to neurotensin with high affinity. The antibody of the present invention neutralizes the activity of neurotensin, in particular the oncogenic activities of neurotensin. In particular, the present invention relates to a neutralizing antibody which binds to the human neurotensin long fragment, and having a heavy chain variable region which comprises a H-CDR1 region having at least 90% of identity with SEQ ID NO:2 in the, a H-CDR2 region having at least 90% of identify with SEQ ID NO:3 and a H-CDR3 region having at least 90% of identity with SEQ ID NO:4; and a light chain variable region comprising a L-CDR1 region having at least 90% of identity with SEQ ID NO:6, a L-CDR2 having at least 90% of identity with SEQ ID NO:7 and a L-CDR3 region having at least 90% of identity with SEQ ID NO:8. The present invention also provides the use of such antibodies in the treatment of cancer.


Find Patent Forward Citations

Loading…